PI4K
Phosphatidylinositol 4 kinases; PI4 kinases
Phosphatidylinositol 4-kinases (PI4Ks) catalyze the synthesis of phosphatidylinositol 4-phosphate (PI4P), an important intermediate for the synthesis of membrane polyphosphoinositides, regulators of multiple cellular functions. PI4P defines the membranes of Golgi and trans-Golgi network (TGN) and regulates trafficking to and from the Golgi. Based on enzymatic differences, two classes of PI4K have been distinguished termed Types II (PI4KII) and III (PI4KIII), and each of which contains α and β isoforms.
PI4KII alpha and beta have similar biochemical properties. PI4KIIIs (α- and β-forms) are soluble enzymes structurally related to PI3-kinases, and sensitive to PI3-kinase inhibitors, such as Wortmannin. PI4KIIs produce PtdIns 4-phosphate, an early key signaling molecule in phosphatidylinositol cycle, which is indispensable for T cell activation. PI4KIIIs plays a key role in the production of replication complexes (viral factories) of a number of positive-sense RNA viruses and represents a potential target for novel pan-viral therapeutics.
PI4K Isoform Specific Products
All Product Categories
-
PI4K Related Products (52)
Related Products (52)
-
PI4K Isoform Comparison
-
BQR-695
0 ImagesSynonyms: NVP-BQR695BQR-695 is a PI4KIIIβ inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.
-
(S)-GSK-F1
0 Images(S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC50 of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model.
-
PI4Kβ/PKG-IN-2
0 ImagesPI4Kβ/PKG-IN-2 (Compound 20) is an orally active dual inhibitor of Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). PI4Kβ/PKG-IN-2 has potent inhibitory effects on Plasmodium. PI4Kβ/PKG-IN-2 is promising for research of malaria.
-
UCT943
0 ImagesUCT943 is a next-generation Plasmodium falciparum PI4K inhibitor. UCT943 inhibits the P. vivax PI4K (PvPI4K) enzyme with an IC50 of 23 nM.
-
CHMFL-PI4K-127
0 ImagesCHMFL-PI4K-127 (compound 15g) is an orally active, potent and high selective PfPI4K (Plasmodium falciparum PI4K kinase) inhibitor, with an IC50 of 0.9 nM. CHMFL-PI4K-127 exhibits potent activity against 3D7 Plasmodium falciparum, with an EC50 of 25.1 nM. CHMFL-PI4K-127 shows antimalaria efficacy.
-
Pi4kb Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10470Pi4kb Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pi4kb gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
PI4KA Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10466PI4KA Human Pre-designed siRNA Set A contains three designed siRNAs for PI4KA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
KAI-407
0 ImagesCat. No.: HY-18746CAS No.: 1513879-18-9KAI-407 is an orally active inhibitor of Plasmodium PI4K kinase, which can broadly inhibit multiple stages of the parasite lifecycle. KAI-407 exhibits EC50s of for the blood stage of malignant Plasmodium of 81 nM; for the liver schizonts of P. yoelii of 88 nM; and IC50s for the liver schizonts and dormant bodies of P. cynomolgi of 0.64 μM and 0.69 μM respectively. KAI-407 can prevent Plasmodium berghei infection 100%. KAI-407 can be used for the study of vivax malaria.
-
PI4KIIIbeta-IN-11
0 ImagesCat. No.: HY-148075CAS No.: 2365241-79-6PI4KIIIbeta-IN-11 is an inhibitor of PI4KIIIβ, with a mean pIC50 value of at least 9.1. PI4KIIIβ plays a key role in diseases research of RNA viruses and Plasmodium falciparum.
-
PI4KIII beta inhibitor 5
0 ImagesCat. No.: HY-172256CAS No.: 3029506-23-5PI4KIII beta inhibitor 5 is a PI4KIIIβ inhibitor with an IC50 of 19 nM. PI4KIII beta inhibitor 5 can induce cancer cell apoptosis (Apoptosis), cell cycle arrest at the G2/M phase, and autophagy (Autophagy) by inhibiting the PI3K/AKT pathway. PI4KIII beta inhibitor 5 has also demonstrated significant antitumor activity in the H446 xenograft model of small cell lung cancer. PI4KIII beta inhibitor 5 can be used for research in the field of cancer therapy.
-
Pi4ka Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10468Pi4ka Rat Pre-designed siRNA Set A contains three designed siRNAs for Pi4ka gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
PI4KB Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10469PI4KB Human Pre-designed siRNA Set A contains three designed siRNAs for PI4KB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
MG degrader 2
0 ImagesCat. No.: HY-177725CAS No.: 2413733-33-0MG degrader 2 (Compound CM-2) is a CRBN-dependent molecular glue degrader. MG degrader 2 induces ZFP91, FIZ1 and PI4KB degradation. MG degrader 2 has anti-proliferative activity against MM.1S cells (IC50 = 162 nM). MG degrader 2 can be used for the research of cancer, such as multiple myeloma.
-
Pi4ka Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10467Pi4ka Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pi4ka gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Antimalarial agent 41
0 ImagesCat. No.: HY-163765Antimalarial agent 41 (Compound 17) exhibits antimalarial activity, which inhibits Plasmodium falciparum with an IC50 of 40 nM (NF54 strain) and 76 nM (K1 strain). Antimalarial agent 41 is an inhibitor for P. falciparum phosphatidylinositol-4-kinase β (Pf PI4K) and hERG channel, with an IC50 of 53 nM and 3 μM. Antimalarial agent 41 exhibits cytotoxicity to CHO cells with an IC50 of 34 μM. Antimalarial agent 41 ameliorates the malaria infection and exhibits good pharmacokinetic characters in mouse models.
-
Pi4kb Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10471Pi4kb Rat Pre-designed siRNA Set A contains three designed siRNAs for Pi4kb gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
KR-27452
0 ImagesCat. No.: HY-179469KR-27452 is a selective and orally active PI4KIIIβ inhibitor with an IC50 of 0.026 μM, while showing no activity against PI4KIIIα (IC50 >10 μM) . KR-27452 specifically binds to and inhibits PI4KIIIβ, leading to reduced viral replication in cells. KR-27452 exhibits strong antiviral activity against human rhinovirus (RVs) and Coxsackievirus (COXs). KR-27452 can be used for the research of infection.
-
PI4KIII beta inhibitor 4
0 ImagesCat. No.: HY-172255CAS No.: 3029505-94-7PI4KIII beta inhibitor 4 (Compound 16) is a selective PI4KIIIβ inhibitor with an IC50 of 0.005 μM. PI4KIIIβ inhibitor 4 induces tumor cell apoptosis, cell cycle arrest, and autophagy by inhibiting the PI3K/AKT pathway. PI4KIIIβ inhibitor 4 can be used in the study of cancer.
